High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1 associated inflammatory arthritis

Research output: Contribution to journalArticle

External organisations

  • University Hospitals Birmingham NHS Foundation Trust

Details

Original languageEnglish
JournalRheumatology
Early online date13 Aug 2018
Publication statusE-pub ahead of print - 13 Aug 2018

Keywords

  • anti-PD-1, anti-PD-L1, pembrolizumab, melanoma, immune-related adverse event, arthritis